RAFA

Rafarma Pharmaceuticals Inc

RAFA, USA

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.

https://rafarma.si

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RAFA
stock
RAFA

2024: nearly 50% of EU electricity came from renewables European Commission

Read more →
RAFA
stock
RAFA

Rocket Lab: High Flying, But Cash Flow Is Still Grounded (NASDAQ:RKLB) Seeking Alpha

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2025-03-31)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.29

Low 1

High 3

Return on Equity (ROE)

-

Very Low

0.71 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

0.62 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-0.36 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.16

Low 1

High 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Rafarma Pharmaceuticals Inc

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-03-31

EPS Actual

0.0008

EPS Estimate

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-03-31)

Deep Value
Strong Deep Value(8)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(8.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1.5)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(5)
Value
Undervalued(8.5)

Income Statement

(Last Updated 2025-03-31)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-03-31)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-03-31)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.